Global Acromegaly Market Professional Survey Report 2019

2 Global Acromegaly Quarterly Market Size Analysis

• 2.1 Acromegaly Business Impact Assessment - COVID-19
  • 2.1.1 Global Acromegaly Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global Acromegaly Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 By Players, Global Acromegaly Quarterly Market Size, 2019 VS 2020
• 3.2 By Players, Acromegaly Headquarters and Area Served
• 3.3 Date of Key Players Enter into Acromegaly Market
• 3.4 Key Players Acromegaly Product Offered
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Acromegaly Segments, By Type

• 4.1 Introduction
  • 1.4.1 Somatostatin Analogues
  • 1.4.2 Dopamine Agonists
  • 1.4.3 Growth Hormone Receptor Antagonists
  • 1.4.4 Other
• 4.2 By Type, Global Acromegaly Market Size, 2019-2021

5 Impact of Covid-19 on Acromegaly Segments, By Application

• 5.1 Overview
  • 5.5.1 Hospitals
  • 5.5.2 Clinics
• 5.2 By Application, Global Acromegaly Market Size, 2019-2021
  • 5.2.1 By Application, Global Acromegaly Market Size by Application, 2019-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 Novartis
  • 7.1.1 Novartis Business Overview
  • 7.1.2 Novartis Acromegaly Quarterly Revenue, 2020
  • 7.1.3 Novartis Acromegaly Product Introduction
  • 7.1.4 Novartis Response to COVID-19 and Related Developments
• 7.2 Aegis Therapeutics
  • 7.2.1 Aegis Therapeutics Business Overview
  • 7.2.2 Aegis Therapeutics Acromegaly Quarterly Revenue, 2020
  • 7.2.3 Aegis Therapeutics Acromegaly Product Introduction
  • 7.2.4 Aegis Therapeutics Response to COVID-19 and Related Developments
• 7.3 Chiasma
  • 7.3.1 Chiasma Business Overview
  • 7.3.2 Chiasma Acromegaly Quarterly Revenue, 2020
  • 7.3.3 Chiasma Acromegaly Product Introduction
  • 7.3.4 Chiasma Response to COVID-19 and Related Developments
• 7.4 Crinetics Pharmaceuticals
  • 7.4.1 Crinetics Pharmaceuticals Business Overview
  • 7.4.2 Crinetics Pharmaceuticals Acromegaly Quarterly Revenue, 2020
  • 7.4.3 Crinetics Pharmaceuticals Acromegaly Product Introduction
  • 7.4.4 Crinetics Pharmaceuticals Response to COVID-19 and Related Developments
• 7.5 Daewoong Pharmaceutical
  • 7.5.1 Daewoong Pharmaceutical Business Overview
  • 7.5.2 Daewoong Pharmaceutical Acromegaly Quarterly Revenue, 2020
  • 7.5.3 Daewoong Pharmaceutical Acromegaly Product Introduction
  • 7.5.4 Daewoong Pharmaceutical Response to COVID-19 and Related Developments
• 7.6 Peptron
  • 7.6.1 Peptron Business Overview
  • 7.6.2 Peptron Acromegaly Quarterly Revenue, 2020
  • 7.6.3 Peptron Acromegaly Product Introduction
  • 7.6.4 Peptron Response to COVID-19 and Related Developments
• 7.7 Silence Therapeutics
  • 7.7.1 Silence Therapeutics Business Overview
  • 7.7.2 Silence Therapeutics Acromegaly Quarterly Revenue, 2020
  • 7.7.3 Silence Therapeutics Acromegaly Product Introduction
  • 7.7.4 Silence Therapeutics Response to COVID-19 and Related Developments
• 7.8 Strongbridge Biopharma
  • 7.8.1 Strongbridge Biopharma Business Overview
  • 7.8.2 Strongbridge Biopharma Acromegaly Quarterly Revenue, 2020
  • 7.8.3 Strongbridge Biopharma Acromegaly Product Introduction
  • 7.8.4 Strongbridge Biopharma Response to COVID-19 and Related Developments
• 7.9 Amryt Pharma
  • 7.9.1 Amryt Pharma Business Overview
  • 7.9.2 Amryt Pharma Acromegaly Quarterly Revenue, 2020
  • 7.9.3 Amryt Pharma Acromegaly Product Introduction
  • 7.9.4 Amryt Pharma Response to COVID-19 and Related Developments
• 7.10 Foresee Pharmaceuticals
  • 7.10.1 Foresee Pharmaceuticals Business Overview
  • 7.10.2 Foresee Pharmaceuticals Acromegaly Quarterly Revenue, 2020
  • 7.10.3 Foresee Pharmaceuticals Acromegaly Product Introduction
  • 7.10.4 Foresee Pharmaceuticals Response to COVID-19 and Related Developments
• 7.11 Glide Pharmaceutical
  • 7.11.1 Glide Pharmaceutical Business Overview
  • 7.11.2 Glide Pharmaceutical Acromegaly Quarterly Revenue, 2020
  • 7.11.3 Glide Pharmaceutical Acromegaly Product Introduction
  • 7.11.4 Glide Pharmaceutical Response to COVID-19 and Related Developments
• 7.12 Ionis Pharmaceuticals
  • 7.12.1 Ionis Pharmaceuticals Business Overview
  • 7.12.2 Ionis Pharmaceuticals Acromegaly Quarterly Revenue, 2020
  • 7.12.3 Ionis Pharmaceuticals Acromegaly Product Introduction
  • 7.12.4 Ionis Pharmaceuticals Response to COVID-19 and Related Developments
• 7.13 Ipsen
  • 7.13.1 Ipsen Business Overview
  • 7.13.2 Ipsen Acromegaly Quarterly Revenue, 2020
  • 7.13.3 Ipsen Acromegaly Product Introduction
  • 7.13.4 Ipsen Response to COVID-19 and Related Developments

8 Key Findings

9 Appendix

• 9.1 About US